tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Denali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating
RatingsDenali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating
40m ago
DNLI
Denali Therapeutics Advances in Neurodegenerative Treatments
PremiumCompany Announcements
Denali Therapeutics Advances in Neurodegenerative Treatments
3h ago
DNLI
Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy Rating
PremiumRatings
Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy Rating
11h ago
DNLI
Denali Therapeutics reports Q2 EPS (72c), consensus (74c)
PremiumThe Fly
Denali Therapeutics reports Q2 EPS (72c), consensus (74c)
14h ago
DNLI
Royalty Pharma appoints Ho, Weatherman to board of directors
PremiumThe Fly
Royalty Pharma appoints Ho, Weatherman to board of directors
26d ago
DNLI
RPRX
Denali Therapeutics: Promising Developments and Strategic Focus Drive Buy Rating
PremiumRatingsDenali Therapeutics: Promising Developments and Strategic Focus Drive Buy Rating
1M ago
DNLI
Denali noted no FDA panel meeting in call with William Blair
Premium
The Fly
Denali noted no FDA panel meeting in call with William Blair
1M ago
DNLI
Denali Therapeutics’ Promising Developments and FDA Milestones Support Buy Rating
Premium
Ratings
Denali Therapeutics’ Promising Developments and FDA Milestones Support Buy Rating
1M ago
DNLI
Denali Therapeutics’ FDA Priority Review for New Therapy
PremiumCompany Announcements
Denali Therapeutics’ FDA Priority Review for New Therapy
1M ago
8K
DNLI
Denali announces FDA acceptance, priority review for tividenofusp alfa BLA
PremiumThe Fly
Denali announces FDA acceptance, priority review for tividenofusp alfa BLA
1M ago
DNLI
Denali Therapeutics Enters Registration Rights Agreement
PremiumCompany Announcements
Denali Therapeutics Enters Registration Rights Agreement
2M ago
8K
DNLI
Denali Therapeutics price target lowered to $27 from $28 at BofA
PremiumThe Fly
Denali Therapeutics price target lowered to $27 from $28 at BofA
3M ago
DNLI
Denali Therapeutics price target lowered to $30 from $35 at B. Riley
PremiumThe FlyDenali Therapeutics price target lowered to $30 from $35 at B. Riley
3M ago
DNLI
Denali Therapeutics price target lowered to $29 from $30 at Baird
Premium
The Fly
Denali Therapeutics price target lowered to $29 from $30 at Baird
3M ago
DNLI
Denali Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
Premium
Ratings
Denali Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
3M ago
DNLI
Denali Therapeutics Advances Pipeline Amid Financial Loss
PremiumCompany Announcements
Denali Therapeutics Advances Pipeline Amid Financial Loss
3M ago
DNLI
Denali Therapeutics price target lowered to $30 from $32 at Wedbush
PremiumThe Fly
Denali Therapeutics price target lowered to $30 from $32 at Wedbush
3M ago
BIIB
DNLI
Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright
PremiumThe Fly
Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright
3M ago
DNLI
Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
PremiumRatings
Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
3M ago
DNLI
Denali Therapeutics reports Q1 EPS (78c), consensus (70c)
PremiumThe FlyDenali Therapeutics reports Q1 EPS (78c), consensus (70c)
3M ago
DNLI
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
4M ago
DNLI
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
4M ago
DNLI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >